Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Gaia BioMedicine, a Japan-based cancer immuno-cellular therapeutics developer spun out of Kyushu University, has secured ¥1.3bn ($11.9m) in a series B round backed by Osaka University Venture Capital (OUVC), a vehicle for Osaka University. The round was led by financial services firm Mitsubishi UFJ subsidiary Mitsubishi UFJ Capital’s Life Science Fund 2 and also included financial services provider SBI subsidiary SBI Investment, pharmaceutical firm Hisamitsu Pharmaceutical and robotics Cyberdyne’s CEJ Capital unit’s CEJ Fund, in addition to its series A investors – all of which remain undisclosed. OUVC had injected $908,000 in June this year but this may have been part of the series B round. Gaia had secured $5.9m in series A financing in February 2020.
Muon Space, a US-based climate-focused satellite constellation company, has received $10m in a seed round backed by University of California-aligned Congruent Ventures. The round was led by Costanoa Ventures, while Space Capital,…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
